Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Long-term Effects Similar for Two-, Three-dose Regimens of Hepatitis A Vaccine




 

Healio (03.19.13) Aids Weekly Plus

Researchers report that a two-dose regimen of hepatitis A vaccine and a three-dose regimen were equally effective after more than 14 years in protecting Alaska Native study participants ages 12 to 24 years. The study compared levels of hepatitis A antibody (anti-HAV) results in two groups. The first group of 101 Alaska Natives between the ages of 12 and 24 initiated two-dose vaccination (720 ELU) for hepatitis A more than five years earlier; a 24-person subgroup received vaccination between the ages of three and six. Researchers compared results for this subgroup with a similar second group who received a three-dose vaccination (360 ELU). Researchers found no significant difference between the groups in “anti-HAV geometric mean concentration (GMC)” according to when immunization was started (ages 1, 2, 3 to 6, and 7). Those who received vaccination at one to two years consistently had the lowest GMC levels. Eleven years after the second dose, GMC levels for 5 percent of the two-dose group were not seroprotective. The two- and three-dose participants also had similar GMC levels 10, 12, and 14 years after vaccination. All two-dose participants and almost all three-dose participants who could be evaluated, continued to have protection from hepatitis A 10, 12, 14, and 15 years after the second dose. The study also found that the three-dose participants were protected after 17 years. Study authors recommended continuing evaluation to determine if and when hepatitis A boosters will be needed. The full report, “Duration of Protection Against Hepatitis A for the Current Two-dose Vaccine Compared to a Three-dose Vaccine Schedule in Children,” was published online in the journal Vaccine (2013; doi:10.1016/j.vaccine.2013.02.048).



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in March 20, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.